<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546649</url>
  </required_header>
  <id_info>
    <org_study_id>TAP-144-SR(6M)IP/CPH-202</org_study_id>
    <secondary_id>JapicCTI-121762</secondary_id>
    <secondary_id>U1111-1128-7039</secondary_id>
    <nct_id>NCT01546649</nct_id>
  </id_info>
  <brief_title>A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated
      against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal
      breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=&lt;30 pg/mL) From Week 4 Through Week 48</measure>
    <time_frame>Week 4 up to Week 48</time_frame>
    <description>Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=&lt;30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Serum E2</measure>
    <time_frame>Baseline, Hour (hr) 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673</time_frame>
    <description>The measure indicates serum E2 concentration at baseline and post-baseline time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Serum Luteinizing Hormone (LH)</measure>
    <time_frame>Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673</time_frame>
    <description>This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673</time_frame>
    <description>This measure indicates serum FSH concentration at baseline and post-baseline time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS) Rate at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>DFS is defined as time from randomization to earliest day of onset the events, recurrence [including recurrence in the ipsilateral breast], secondary cancer [including breast cancer in the contralateral breast] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Disease Free Survival (DDFS) Rate at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer [including breast cancer in the contralateral breast] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Unchanged TAP-144 Level</measure>
    <time_frame>Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309 and 337</time_frame>
    <description>This measure indicates the unchanged TAP-144 level in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT Interval Measured by 12-lead Electrocardiogram (ECG)</measure>
    <time_frame>Baseline, Hour 1, 3, 6 on Day 1, Day 29, 85, 169 and 337</time_frame>
    <description>12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Premenopausal Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TAP-144-SR(6M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP-144-SR(3M)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAP-144-SR(6M)</intervention_name>
    <arm_group_label>TAP-144-SR(6M)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAP-144-SR(3M)</intervention_name>
    <arm_group_label>TAP-144-SR(3M)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant has histopathologically-confirmed primary breast cancer in Japanese.

          2. The participant is aged 20 years or older when informed consent is obtained

          3. The participant has estrogen receptor (ER)-positive tumor cells and/or progesterone
             receptor (PgR)-positive primary tumor. And HER-2 is negative.

          4. The participant has breast cancer in the clinical stages of T1-T3, N-any and M0 by TNM
             classification (the seventh edition, proposed by UICC in 2009). (No distant metastasis
             to lung, liver and bone should be confirmed on the image-based diagnosis at study
             enrollment. The image taken within 12 weeks prior to study enrollment is also
             available for the diagnosis.) The number of axillary lymph node metastasis is not
             limited.

          5. Any operative procedure for breast cancer is acceptable. In principle, after
             breast-conserving surgery, the participant will receive postoperative radiation to the
             conserving breast.

          6. Neoadjuvant chemotherapy and adjuvant chemotherapy prior to study enrollment are
             acceptable. (It is advisable the same kind of chemotherapy is performed at each site.)

          7. The participant has a history of regular menstrual periods within 12 weeks prior to
             study enrollment, or the participant has FSH of less than 40 mIU/mL and E2 of 10 pg/mL
             or more measured within 12 weeks prior to study enrollment. The participant has not
             had a chemical menopause (i.e., FSH of less than 40 mIU/mL and E2 of 10 pg/mL or more)
             within 12 weeks after completing adjuvant chemotherapy.

          8. The participant is in a condition to receive study drug and Tamoxifen (TAM) within 12
             weeks after surgery or after adjuvant chemotherapy prior to study enrollment. Adjuvant
             chemotherapy prior to study is required to have been completed at the time of study
             enrollment.

          9. The participant has ECOG performance status of grades 0 or 1 at the time of study
             enrollment.

         10. The participant meets the following criteria of hepatic, renal and bone marrow
             functions on the laboratory test results at screening:

               -  Hepatic function: AST (GOT) ≤ 3.0 times the upper limit of normal (ULN) ALT (GPT)
                  ≤ 3.0 times the ULN

               -  Renal function: serum creatinine level &lt; 1.5 times the ULN

               -  Bone marrow function : white blood cell count ≥ 3,000/mm3 platelet count ≥
                  100,000/μL hemoglobin ≥ 10.0g/dL

         11. The participant agrees to use a non-hormonal method of contraception through the study
             period.

        Exclusion Criteria:

          1. The participant has received neoadjuvant or adjuvant hormonal therapy for the latest
             breast cancer surgery.

          2. The participant has received bilateral oophorectomy and bilateral ovarian irradiation.

          3. The participant has inflammatory breast cancer or bilateral breast cancer.

          4. The participant has non-invasive ductal carcinoma.

          5. The participant has multiple primary cancers, or a history of carcinoma in other
             organs.

          6. The participant is pregnant or breast-feeding.

          7. The participant has a history of hypersensitivity to synthetic LH-RH, LH-RH
             derivative, TAM, TAM analogue (antiestrogen) or any component of the study drug.

          8. The participant has a history of, or has been diagnosed with thromboembolism including
             myocardial infarction, cerebral infarction, venous thrombosis, and pulmonary embolism,
             or cardiac failure.

          9. Patients whose QTcF interval exceeded 460 msec on the 12-lead electrocardiogram at
             screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukushima-shi</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohta-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isehara-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nigata-shi</city>
        <state>Nigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita-adachi-gun</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <results_first_submitted>October 22, 2015</results_first_submitted>
  <results_first_submitted_qc>October 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2015</results_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 21 investigative sites in Japan from April 2012 to December 2014.</recruitment_details>
      <pre_assignment_details>Participants with a historical diagnosis of premenopausal breast cancer were enrolled in 1 of 2 treatment groups as follows: TAP-144-SR(6M); TAP-144-SR(3M)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAP-144-SR (6M)</title>
          <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
        </group>
        <group group_id="P2">
          <title>TAP-144-SR (3M)</title>
          <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recurrence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discovery of secondary cancer</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all randomized participants who had received at least a single dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>TAP-144-SR (6M)</title>
          <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
        </group>
        <group group_id="B2">
          <title>TAP-144-SR (3M)</title>
          <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="4.90"/>
                    <measurement group_id="B2" value="44.0" spread="5.18"/>
                    <measurement group_id="B3" value="44.1" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than equal to (&gt;=) 40 to &lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159.3" spread="5.11"/>
                    <measurement group_id="B2" value="158.1" spread="5.00"/>
                    <measurement group_id="B3" value="158.7" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;150 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=150 to &lt;160 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=160 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.48" spread="7.670"/>
                    <measurement group_id="B2" value="53.57" spread="7.498"/>
                    <measurement group_id="B3" value="54.02" spread="7.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;50 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 to &lt;60 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=60 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.50" spread="3.042"/>
                    <measurement group_id="B2" value="21.45" spread="2.902"/>
                    <measurement group_id="B3" value="21.48" spread="2.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18.5 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=18.5 to &lt;25.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=25.0 to &lt;30.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30.0 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical procedure, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Breast-conserving surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mastectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pathological diagnosis, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Papillotubular carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solid-tubular carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scirrhous carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucinous carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Invasive lobular carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tubular adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Invasive micropapillary carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specified neoplasms (other)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNM classification: clinical tumor stage T, Customized</title>
          <description>The frequency of clinical tumor stage T (0, 1, 2, 3, 4, X, or Tis) was assessed. The frequency of T was evaluated prior to surgery. The categories of T are ranged from 0 (No evidence of primary tumor) to 4 (Tumor of any size with direct extension to chest wall and/or to skin). X is representing tumor cannot be evaluated, 0 is representing no signs of tumor, Tis is carcinoma in situ.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNM classification: regional lymph node stage N, Customized</title>
          <description>The frequency of regional lymph nodes stage N (0, 1, 2, 3, or X) was assessed. The frequency of N was evaluated prior to surgery. The categories of N are ranged from 0 (No regional lymph node metastasis) to 3 (Metastasis in ipsilateral infraclavicular lymph node(s); or in clinically detected ipsilateral internal mammary lymph node(s); or metastasis in ipsilateral supraclavicular lymph node(s)). X is representing lymph nodes cannot be evaluated, 0 is tumor cells absent from regional lymph nodes.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>N0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNM classification: M0</title>
          <description>The frequency of distant metastasis clinical stage M (0, 1) was assessed. The frequency of M was evaluated prior to surgery. The categories of M are represented by 0 (no distant metastasis) and 1 (distant metastasis).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNM staging (Stage), Customized</title>
          <description>The stage of cancer based on TNM classification: Stage 0 (Carcinoma in situ which is staged by Tis, N0, M0), Stage IA (T1, N0, M0), IB (T0/T1, N1, M0), IIA (T0/T1, N1, M0 or T2, N0, M0), IIB (T2, N1, M0 or T3, N0, M0), IIIA (T0/T1/T2, N2, M0 or T3, N1/N2, M0), IIIB (T4, N0/N1/N2, M0) and IIIC (Any T, N3, M0), Stage IV(Any T, Any N, M1).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histopathological tumor size</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.64" spread="1.312"/>
                    <measurement group_id="B2" value="1.55" spread="1.023"/>
                    <measurement group_id="B3" value="1.59" spread="1.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histopathological tumor size, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than equal to (&lt;=) 2.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2.0 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axillary lymph node metastases</title>
          <units>number of metastases</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.2" spread="0.46"/>
                    <measurement group_id="B2" value="0.2" spread="0.57"/>
                    <measurement group_id="B3" value="0.2" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axillary lymph node metastases, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axillary lymph node metastases, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 metastasis to &lt;=3 metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=4 metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from surgery or previous postoperative adjuvant therapy to administration of study drug</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=28 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=29 to &lt;=56 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=57 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary tumor estrogen receptors (ER)/ progesterone receptors (PgR) status, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ER -positive / PgR-positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER -positive / PgR -negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER -negative / PgR -positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human epidermal growth factor receptor 2 (HER2) (immunohistochemistry [IHC] scoring), Customized</title>
          <description>Participants with HER expression by IHC was reported as 0, 1+, 2+, 3+, or unmeasured. The categories of HER expression is ranged from 0 (better) to 3+ (worse).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not performed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HER2 (fluorescent in situ hybridization [FISH] testing), Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Equivocal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not performed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The eastern cooperative oncology group performance status (ECOG P.S.), Customized</title>
          <description>Following are ECOG grades. 0: Fully active, perform all pre-disease activities without restriction. 1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (&gt;) 50% of waking hours. 3: Capable of limited selfcare, confined to bed or chair &gt;50% of waking hours. 4: Completely disabled, not capable of any selfcare, totally confined to bed or chair.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menstruation (before the first dose), Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from last menstruation to first dose</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.0" spread="13.27"/>
                    <measurement group_id="B2" value="15.9" spread="14.28"/>
                    <measurement group_id="B3" value="16.4" spread="13.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from last menstruation to first dose, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=28 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=29 to &lt;=56 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=57 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Estradiol (E2) concentration (pretreatment)</title>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.0" spread="162.99"/>
                    <measurement group_id="B2" value="138.2" spread="125.45"/>
                    <measurement group_id="B3" value="153.0" spread="145.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum E2 concentration (pretreatment), Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=29 pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Radiation, Customized</title>
          <description>Participants were classified based on whether they had received radiation therapy or not.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative and postoperative chemotherapy, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous breast cancer (other), Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant osteoporosis medication , Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from surgery or previous postoperative adjuvant therapy to administration of study drug</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="21.69"/>
                    <measurement group_id="B2" value="51.8" spread="16.01"/>
                    <measurement group_id="B3" value="53.6" spread="19.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=&lt;30 pg/mL) From Week 4 Through Week 48</title>
        <description>Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=&lt;30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.</description>
        <time_frame>Week 4 up to Week 48</time_frame>
        <population>Full analysis set (FAS) included all randomized participants who had received at least a single dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR (6M)</title>
            <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR (3M)</title>
            <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=&lt;30 pg/mL) From Week 4 Through Week 48</title>
          <description>Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=&lt;30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.</description>
          <population>Full analysis set (FAS) included all randomized participants who had received at least a single dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="91.565" upper_limit="99.707"/>
                    <measurement group_id="O2" value="96.4" lower_limit="89.916" upper_limit="99.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Serum E2</title>
        <description>The measure indicates serum E2 concentration at baseline and post-baseline time points.</description>
        <time_frame>Baseline, Hour (hr) 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673</time_frame>
        <population>FAS included all randomized participants who had received at least a single dose of study treatment. Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR (6M)</title>
            <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR (3M)</title>
            <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Serum E2</title>
          <description>The measure indicates serum E2 concentration at baseline and post-baseline time points.</description>
          <population>FAS included all randomized participants who had received at least a single dose of study treatment. Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="0" upper_limit="652"/>
                    <measurement group_id="O2" value="99" lower_limit="0" upper_limit="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (1hr) [N=82;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="0" upper_limit="616"/>
                    <measurement group_id="O2" value="110.5" lower_limit="0" upper_limit="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (3hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.0" lower_limit="0" upper_limit="602"/>
                    <measurement group_id="O2" value="64.0" lower_limit="15" upper_limit="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (6hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.5" lower_limit="0" upper_limit="681"/>
                    <measurement group_id="O2" value="99.0" lower_limit="16" upper_limit="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day2 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.0" lower_limit="0" upper_limit="693"/>
                    <measurement group_id="O2" value="115.5" lower_limit="0" upper_limit="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day3 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="0" upper_limit="417"/>
                    <measurement group_id="O2" value="87.5" lower_limit="0" upper_limit="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day4 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.0" lower_limit="0" upper_limit="543"/>
                    <measurement group_id="O2" value="110.0" lower_limit="0" upper_limit="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Day8) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="0" upper_limit="904"/>
                    <measurement group_id="O2" value="112.0" lower_limit="0" upper_limit="981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Day15) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="0" upper_limit="866"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (Day22) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="196"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Day29) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Day57) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Day85) [N=83;83]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Day113) [N=82;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="69"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (Day141) [N=81;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Day169) [N=80;81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 (Day176) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="18"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (Day183) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Day197) [N=75;77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (Day225) [N=78;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="17"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (Day253) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="18"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (Day281) [N=78;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="184"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (Day309) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (Day337) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Day421) [N=77;79]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (Day505) [N=77;78]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (Day589) [N=76;77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (Day673) [N=75;75]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Serum Luteinizing Hormone (LH)</title>
        <description>This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).</description>
        <time_frame>Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673</time_frame>
        <population>FAS included all randomized participants who had received at least a single dose of study treatment. Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR (6M)</title>
            <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR (3M)</title>
            <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Serum Luteinizing Hormone (LH)</title>
          <description>This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).</description>
          <population>FAS included all randomized participants who had received at least a single dose of study treatment. Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
          <units>mIU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.250" lower_limit="0.69" upper_limit="65.33"/>
                    <measurement group_id="O2" value="4.490" lower_limit="0.77" upper_limit="40.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (1hr) [N=82;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.730" lower_limit="8.12" upper_limit="250.00"/>
                    <measurement group_id="O2" value="30.585" lower_limit="2.78" upper_limit="207.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (3hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.020" lower_limit="24.64" upper_limit="250.00"/>
                    <measurement group_id="O2" value="63.260" lower_limit="12.00" upper_limit="153.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (6hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.750" lower_limit="32.54" upper_limit="198.90"/>
                    <measurement group_id="O2" value="61.210" lower_limit="12.68" upper_limit="106.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day2 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.990" lower_limit="3.22" upper_limit="90.63"/>
                    <measurement group_id="O2" value="19.755" lower_limit="1.84" upper_limit="154.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day3 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.310" lower_limit="1.28" upper_limit="27.86"/>
                    <measurement group_id="O2" value="10.500" lower_limit="1.73" upper_limit="59.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day4 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.830" lower_limit="1.13" upper_limit="41.16"/>
                    <measurement group_id="O2" value="9.375" lower_limit="1.63" upper_limit="56.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Day8) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.190" lower_limit="0.75" upper_limit="25.08"/>
                    <measurement group_id="O2" value="4.475" lower_limit="1.18" upper_limit="29.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Day15) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.460" lower_limit="0.76" upper_limit="10.56"/>
                    <measurement group_id="O2" value="1.990" lower_limit="0.75" upper_limit="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (Day22) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.020" lower_limit="0.24" upper_limit="4.39"/>
                    <measurement group_id="O2" value="1.085" lower_limit="0.38" upper_limit="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Day29) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.540" lower_limit="0.16" upper_limit="1.85"/>
                    <measurement group_id="O2" value="0.845" lower_limit="0.33" upper_limit="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Day57) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.270" lower_limit="0.00" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.570" lower_limit="0.00" upper_limit="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Day85) [N=83;83]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.220" lower_limit="0.00" upper_limit="1.84"/>
                    <measurement group_id="O2" value="0.520" lower_limit="0.00" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Day113) [N=82;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.245" lower_limit="0.00" upper_limit="7.08"/>
                    <measurement group_id="O2" value="0.430" lower_limit="0.00" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (Day141) [N=81;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.240" lower_limit="0.00" upper_limit="2.26"/>
                    <measurement group_id="O2" value="0.405" lower_limit="0.00" upper_limit="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Day169) [N=80;81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.290" lower_limit="0.00" upper_limit="8.01"/>
                    <measurement group_id="O2" value="0.460" lower_limit="0.11" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 (Day176) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.450" lower_limit="0.00" upper_limit="7.92"/>
                    <measurement group_id="O2" value="0.455" lower_limit="0.15" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (Day183) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410" lower_limit="0.12" upper_limit="2.46"/>
                    <measurement group_id="O2" value="0.405" lower_limit="0.14" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Day197) [N=75;77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.270" lower_limit="0.11" upper_limit="0.95"/>
                    <measurement group_id="O2" value="0.410" lower_limit="0.11" upper_limit="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (Day225) [N=78;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.280" lower_limit="0.00" upper_limit="1.31"/>
                    <measurement group_id="O2" value="0.440" lower_limit="0.14" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (Day253) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.00" upper_limit="2.02"/>
                    <measurement group_id="O2" value="0.395" lower_limit="0.11" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (Day281) [N=78;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.240" lower_limit="0.00" upper_limit="2.05"/>
                    <measurement group_id="O2" value="0.390" lower_limit="0.12" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (Day309) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.00" upper_limit="2.67"/>
                    <measurement group_id="O2" value="0.385" lower_limit="0.00" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (Day337) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.00" upper_limit="2.12"/>
                    <measurement group_id="O2" value="0.415" lower_limit="0.11" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Day421) [N=77;79]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.00" upper_limit="1.52"/>
                    <measurement group_id="O2" value="0.440" lower_limit="0.00" upper_limit="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (Day505) [N=77;78]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.260" lower_limit="0.00" upper_limit="1.24"/>
                    <measurement group_id="O2" value="0.420" lower_limit="0.00" upper_limit="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (Day589) [N=76;77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.230" lower_limit="0.00" upper_limit="1.30"/>
                    <measurement group_id="O2" value="0.410" lower_limit="0.00" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (Day673) [N=75;75]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.210" lower_limit="0.00" upper_limit="1.48"/>
                    <measurement group_id="O2" value="0.360" lower_limit="0.00" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Follicle Stimulating Hormone (FSH)</title>
        <description>This measure indicates serum FSH concentration at baseline and post-baseline time points.</description>
        <time_frame>Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673</time_frame>
        <population>FAS included all randomized participants who had received at least a single dose of study treatment. Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR (6M)</title>
            <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR (3M)</title>
            <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Follicle Stimulating Hormone (FSH)</title>
          <description>This measure indicates serum FSH concentration at baseline and post-baseline time points.</description>
          <population>FAS included all randomized participants who had received at least a single dose of study treatment. Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
          <units>mIU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.070" lower_limit="1.97" upper_limit="57.33"/>
                    <measurement group_id="O2" value="5.605" lower_limit="2.03" upper_limit="66.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (1hr) [N=82;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.520" lower_limit="4.01" upper_limit="102.42"/>
                    <measurement group_id="O2" value="10.000" lower_limit="4.02" upper_limit="99.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (3hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.325" lower_limit="8.39" upper_limit="110.28"/>
                    <measurement group_id="O2" value="19.950" lower_limit="10.06" upper_limit="74.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (6hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.460" lower_limit="11.19" upper_limit="147.78"/>
                    <measurement group_id="O2" value="25.340" lower_limit="10.85" upper_limit="107.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day2 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.080" lower_limit="2.78" upper_limit="93.70"/>
                    <measurement group_id="O2" value="12.515" lower_limit="3.23" upper_limit="115.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day3 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.180" lower_limit="2.86" upper_limit="45.56"/>
                    <measurement group_id="O2" value="6.780" lower_limit="3.09" upper_limit="55.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day4 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.100" lower_limit="2.84" upper_limit="37.79"/>
                    <measurement group_id="O2" value="5.585" lower_limit="2.75" upper_limit="36.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Day8) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.920" lower_limit="0.99" upper_limit="14.09"/>
                    <measurement group_id="O2" value="3.035" lower_limit="1.19" upper_limit="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Day15) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.820" lower_limit="0.58" upper_limit="7.49"/>
                    <measurement group_id="O2" value="1.705" lower_limit="0.47" upper_limit="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (Day22) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.220" lower_limit="0.49" upper_limit="3.22"/>
                    <measurement group_id="O2" value="1.570" lower_limit="0.49" upper_limit="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Day29) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.200" lower_limit="0.39" upper_limit="2.48"/>
                    <measurement group_id="O2" value="2.015" lower_limit="0.68" upper_limit="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Day57) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.390" lower_limit="0.36" upper_limit="5.15"/>
                    <measurement group_id="O2" value="2.345" lower_limit="0.87" upper_limit="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Day85) [N=83;83]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.490" lower_limit="0.37" upper_limit="5.72"/>
                    <measurement group_id="O2" value="2.240" lower_limit="0.76" upper_limit="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Day113) [N=82;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.635" lower_limit="0.59" upper_limit="11.04"/>
                    <measurement group_id="O2" value="1.830" lower_limit="0.69" upper_limit="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (Day141) [N=81;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.780" lower_limit="0.53" upper_limit="7.28"/>
                    <measurement group_id="O2" value="1.905" lower_limit="0.87" upper_limit="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Day169) [N=80;81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.060" lower_limit="0.42" upper_limit="6.24"/>
                    <measurement group_id="O2" value="2.000" lower_limit="0.59" upper_limit="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 (Day176) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.940" lower_limit="0.71" upper_limit="5.22"/>
                    <measurement group_id="O2" value="1.600" lower_limit="0.51" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (Day183) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.560" lower_limit="0.53" upper_limit="3.40"/>
                    <measurement group_id="O2" value="1.700" lower_limit="0.64" upper_limit="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Day197) [N=75;77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.310" lower_limit="0.52" upper_limit="2.81"/>
                    <measurement group_id="O2" value="1.690" lower_limit="0.59" upper_limit="5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (Day225) [N=78;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.595" lower_limit="0.52" upper_limit="4.81"/>
                    <measurement group_id="O2" value="1.980" lower_limit="0.57" upper_limit="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (Day253) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.660" lower_limit="0.73" upper_limit="6.12"/>
                    <measurement group_id="O2" value="2.035" lower_limit="0.67" upper_limit="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (Day281) [N=78;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.735" lower_limit="0.75" upper_limit="4.09"/>
                    <measurement group_id="O2" value="1.710" lower_limit="0.71" upper_limit="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (Day309) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.930" lower_limit="0.72" upper_limit="5.01"/>
                    <measurement group_id="O2" value="1.825" lower_limit="0.70" upper_limit="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (Day337) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.920" lower_limit="0.69" upper_limit="8.37"/>
                    <measurement group_id="O2" value="1.885" lower_limit="0.72" upper_limit="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60 (Day421) [N=77;79]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.530" lower_limit="0.74" upper_limit="4.71"/>
                    <measurement group_id="O2" value="1.910" lower_limit="0.64" upper_limit="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (Day505) [N=77;78]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.730" lower_limit="0.92" upper_limit="5.89"/>
                    <measurement group_id="O2" value="1.920" lower_limit="0.63" upper_limit="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84 (Day589) [N=76;77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="0.77" upper_limit="3.23"/>
                    <measurement group_id="O2" value="1.840" lower_limit="0.66" upper_limit="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 (Day673) [N=75;75]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.620" lower_limit="0.76" upper_limit="4.57"/>
                    <measurement group_id="O2" value="1.740" lower_limit="0.59" upper_limit="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival (DFS) Rate at Week 96</title>
        <description>DFS is defined as time from randomization to earliest day of onset the events, recurrence [including recurrence in the ipsilateral breast], secondary cancer [including breast cancer in the contralateral breast] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.</description>
        <time_frame>Week 96</time_frame>
        <population>FAS included all randomized participants who had received at least a single dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR (6M)</title>
            <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR (3M)</title>
            <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS) Rate at Week 96</title>
          <description>DFS is defined as time from randomization to earliest day of onset the events, recurrence [including recurrence in the ipsilateral breast], secondary cancer [including breast cancer in the contralateral breast] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.</description>
          <population>FAS included all randomized participants who had received at least a single dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3"/>
                    <measurement group_id="O2" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distant Disease Free Survival (DDFS) Rate at Week 96</title>
        <description>DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer [including breast cancer in the contralateral breast] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.</description>
        <time_frame>Week 96</time_frame>
        <population>FAS included all randomized participants who had received at least a single dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR (6M)</title>
            <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR (3M)</title>
            <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Distant Disease Free Survival (DDFS) Rate at Week 96</title>
          <description>DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer [including breast cancer in the contralateral breast] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.</description>
          <population>FAS included all randomized participants who had received at least a single dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Unchanged TAP-144 Level</title>
        <description>This measure indicates the unchanged TAP-144 level in serum.</description>
        <time_frame>Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309 and 337</time_frame>
        <population>FAS included all randomized participants who had received at least a single dose of study treatment. Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR (6M)</title>
            <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR (3M)</title>
            <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Unchanged TAP-144 Level</title>
          <description>This measure indicates the unchanged TAP-144 level in serum.</description>
          <population>FAS included all randomized participants who had received at least a single dose of study treatment. Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
          <units>nanogram per deciliter (ng/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000" lower_limit="0.69" upper_limit="65.33"/>
                    <measurement group_id="O2" value="0.000" spread="0.0000" lower_limit="0.77" upper_limit="40.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (1hr) [N=82;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.293" spread="1.0684" lower_limit="8.12" upper_limit="250.00"/>
                    <measurement group_id="O2" value="28.45" spread="9.7398" lower_limit="2.78" upper_limit="207.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (3hr) [N=24;19]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.538" spread="0.46023" lower_limit="24.64" upper_limit="250.00"/>
                    <measurement group_id="O2" value="20.27" spread="3.9535" lower_limit="12.00" upper_limit="153.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (6hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039" spread="0.23264" lower_limit="32.54" upper_limit="198.90"/>
                    <measurement group_id="O2" value="8.037" spread="1.7408" lower_limit="12.68" upper_limit="106.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day2 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1401" spread="0.066137" lower_limit="3.22" upper_limit="90.63"/>
                    <measurement group_id="O2" value="0.4749" spread="0.17801" lower_limit="1.84" upper_limit="154.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day3 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02889" spread="0.026108" lower_limit="1.28" upper_limit="27.86"/>
                    <measurement group_id="O2" value="0.2492" spread="0.097054" lower_limit="1.73" upper_limit="59.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day4 [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02380" spread="0.022645" lower_limit="1.13" upper_limit="41.16"/>
                    <measurement group_id="O2" value="0.2273" spread="0.080794" lower_limit="1.63" upper_limit="56.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (Day8) [N=82;83]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09115" spread="0.22637" lower_limit="0.75" upper_limit="25.08"/>
                    <measurement group_id="O2" value="0.1050" spread="0.049062" lower_limit="1.18" upper_limit="29.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (Day15) [N=82;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3702" spread="0.25134" lower_limit="0.76" upper_limit="10.56"/>
                    <measurement group_id="O2" value="0.08867" spread="0.077142" lower_limit="0.75" upper_limit="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (Day22) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7285" spread="0.35639" lower_limit="0.24" upper_limit="4.39"/>
                    <measurement group_id="O2" value="0.06471" spread="0.092279" lower_limit="0.38" upper_limit="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Day29) [N=83;83]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3442" spread="0.19814" lower_limit="0.16" upper_limit="1.85"/>
                    <measurement group_id="O2" value="0.04971" spread="0.032917" lower_limit="0.33" upper_limit="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Day57) [N=83;83]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1146" spread="0.053068" lower_limit="0.00" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.04744" spread="0.032379" lower_limit="0.00" upper_limit="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Day85) [N=83;83]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08051" spread="0.041881" lower_limit="0.00" upper_limit="1.84"/>
                    <measurement group_id="O2" value="0.06028" spread="0.031104" lower_limit="0.00" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Day113) [N=82;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05775" spread="0.037098" lower_limit="0.00" upper_limit="7.08"/>
                    <measurement group_id="O2" value="0.09347" spread="0.077284" lower_limit="0.00" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (Day141) [N=81;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03941" spread="0.037082" lower_limit="0.00" upper_limit="2.26"/>
                    <measurement group_id="O2" value="0.07165" spread="0.062739" lower_limit="0.00" upper_limit="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Day169) [N=80;81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02931" spread="0.019785" lower_limit="0.00" upper_limit="8.01"/>
                    <measurement group_id="O2" value="0.07634" spread="0.064118" lower_limit="0.11" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 (Day176) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1128" spread="0.16751" lower_limit="0.00" upper_limit="7.92"/>
                    <measurement group_id="O2" value="0.1583" spread="0.089299" lower_limit="0.15" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (Day183) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3327" spread="0.36474" lower_limit="0.12" upper_limit="2.46"/>
                    <measurement group_id="O2" value="0.1109" spread="0.065133" lower_limit="0.14" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Day197) [N=80;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4687" spread="0.36083" lower_limit="0.11" upper_limit="0.95"/>
                    <measurement group_id="O2" value="0.08468" spread="0.040820" lower_limit="0.11" upper_limit="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (Day225) [N=78;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1377" spread="0.093340" lower_limit="0.00" upper_limit="1.31"/>
                    <measurement group_id="O2" value="0.06881" spread="0.037607" lower_limit="0.14" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (Day253) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08521" spread="0.040324" lower_limit="0.00" upper_limit="2.02"/>
                    <measurement group_id="O2" value="0.06259" spread="0.036687" lower_limit="0.11" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (Day281) [N=79;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06073" spread="0.032232" lower_limit="0.00" upper_limit="2.05"/>
                    <measurement group_id="O2" value="0.08163" spread="0.031631" lower_limit="0.12" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (Day309) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4339" spread="0.026552" lower_limit="0.00" upper_limit="2.67"/>
                    <measurement group_id="O2" value="0.06479" spread="0.028540" lower_limit="0.00" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (Day337) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02957" spread="0.017147" lower_limit="0.00" upper_limit="2.12"/>
                    <measurement group_id="O2" value="0.06313" spread="0.032149" lower_limit="0.11" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QT Interval Measured by 12-lead Electrocardiogram (ECG)</title>
        <description>12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).</description>
        <time_frame>Baseline, Hour 1, 3, 6 on Day 1, Day 29, 85, 169 and 337</time_frame>
        <population>Safety evaluation was conducted in the safety analysis set (SAS). Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR (6M)</title>
            <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR (3M)</title>
            <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>QT Interval Measured by 12-lead Electrocardiogram (ECG)</title>
          <description>12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).</description>
          <population>Safety evaluation was conducted in the safety analysis set (SAS). Here ‘N’ represents evaluable baseline and post-baseline assessment population.</population>
          <units>millisecond (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421.5" spread="16.05" lower_limit="0.69" upper_limit="65.33"/>
                    <measurement group_id="O2" value="420.9" spread="16.53" lower_limit="0.77" upper_limit="40.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (1hr) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.8" spread="15.37" lower_limit="8.12" upper_limit="250.00"/>
                    <measurement group_id="O2" value="417.1" spread="17.83" lower_limit="2.78" upper_limit="207.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (3hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.8" spread="11.34" lower_limit="24.64" upper_limit="250.00"/>
                    <measurement group_id="O2" value="423.7" spread="18.90" lower_limit="12.00" upper_limit="153.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 (6hr) [N=24;21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.8" spread="18.68" lower_limit="32.54" upper_limit="198.90"/>
                    <measurement group_id="O2" value="424.1" spread="13.76" lower_limit="12.68" upper_limit="106.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Day29) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431.2" spread="19.30" lower_limit="0.16" upper_limit="1.85"/>
                    <measurement group_id="O2" value="432.3" spread="16.90" lower_limit="0.33" upper_limit="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Day85) [N=83;84]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433.3" spread="19.44" lower_limit="0.00" upper_limit="1.84"/>
                    <measurement group_id="O2" value="432.3" spread="20.01" lower_limit="0.00" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Day169) [N=81;82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431.0" spread="21.22" lower_limit="0.00" upper_limit="8.01"/>
                    <measurement group_id="O2" value="429.0" spread="20.28" lower_limit="0.11" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (Day337) [N=77;80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.0" spread="17.31" lower_limit="0.00" upper_limit="2.12"/>
                    <measurement group_id="O2" value="431.4" spread="18.89" lower_limit="0.11" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAP-144-SR (6M)</title>
          <description>TAP-144-SR (6M) 22.5 milligram (mg), injection, subcutaneous, once in 24 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
        </group>
        <group group_id="E2">
          <title>TAP-144-SR (3M)</title>
          <description>TAP-144-SR (3M) 11.25 mg, injection, subcutaneous, once in 12 weeks along with tamoxifen 20 mg, tablet, orally, once daily for up to 96 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Behcet's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Bone density decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

